Latest News

Thursday, September 22, 2016 | Movement Disorders

WPC 2016: Study Elucidates the Role of Neuroinflammation in Pre-diagnosis Parkinson’s Disease

Anti-inflammatory agents could possibly delay progression to a manifest synucleinopathy in subjects with idiopathic REM sleep behaviour disorder (IRBD), according to new findings presented at the ongo…

Read the full story

Wednesday, September 21, 2016 | Movement Disorders

AANEM 2016: Dysport Found Effective at 2 mL Dilution in Cervical Dystonia

A 12-week study presented at the American Association of Neuromuscular & Electrodiagnostic Medicine (AANEM) suggests that a 2 mL dilution of abobotulinumtoxinA (Dysport, Ipsen) may …

Read the full story

Friday, September 16, 2016 | Phase 3/4 Trials, Research and Publications

ECTRIMS: Six-Year Extension Data Elucidate Benefits of Alemtuzumab in Treating Relapsing MS

New six-year extension data presented at the Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) suggest that patients treated with Lemtrada (alemtuzumab, San…

Read the full story

Friday, September 16, 2016 | Personnel/Company News

Epilepsy Foundation Unveils New Report, Social Media Hash Tag for SUDEP Awareness Initiative

The Epilepsy Foundation’s SUDEP Institute issued a expert consensus report as part of its social media campaign to motivate people with epilepsy to reduce their risk of Sudden Unexpected Death i…

Read the full story

Thursday, September 15, 2016 | Personnel/Company News

NIH Awards Neural Analytics $3 Million Grant to Study Portable Brain Monitoring Platform

Neural Analytics Inc. has received a $3 million grant from the National Institutes of Health (NIH) to support a clinical validation study of its portable brain monitoring platform. The grant is suppor…

Read the full story

Thursday, September 15, 2016 | Research and Publications, Biogen

ECTRIMS: Results from DECIDE Trial Affirm Benefits of Zinbryta

A new post-hoc analysis from the pivotal DECIDE study shows that a significantly greater number of people treated with Zinbryta (daclizumab, Biogen/AbbVie) achieved no evidence of disease activity (NE…

Read the full story

Thursday, September 15, 2016 | Research and Publications

ECTRIMS: Adoption of New MRI Criteria May Lead to Earlier Diagnosis

Adopting the new guidelines for the use of MRI in the diagnosis of multiple sclerosis (MS) may lead to earlier diagnosis, according to new findings presented at ECTRIMS. The new guidelines, the r…

Read the full story

Wednesday, September 14, 2016 |

Parkinson’s Disease Foundation Launches Live Seminar Series

The Parkinson's Disease Foundation recently launched its eighth series of PD ExpertBriefings -- six free online seminars which address unmet needs in Parkinson's education. The series o…

Read the full story

Wednesday, September 14, 2016 |

Investigational Low-Dose Fenfluramine Found Effective as Adjunctive Therapy in Dravet Syndrome

Data from a new patient cohort in an ongoing open-label study suggests that an investigational low-dose fenfluramine liquid solution may offer benefit as an adjunctive therapy for seizures associated …

Read the full story

Wednesday, September 07, 2016 | Research and Publications

Vaccine against Alpha-Synuclein Increases Immune Response in Parkinson’s Disease in Phase I Study

Results from a Phase I clinical trial suggest that boost immunizations with AFFITOPE® PD01A (AFFiRiS), an active vaccine against a protein that’s thought to play a role in Parkinson´s …

Read the full story

Friday, September 02, 2016 | FDA Approval/Clearance

FDA Fast Tracks Biogen’s Aducanumab for Alzheimer’s Disease

The FDA has granted Fast Track designation to Biogen for aducanumab, an investigational human recombinant monoclonal antibody for early Alzheimer’s disease (AD). The new designation comes on the…

Read the full story

Thursday, September 01, 2016 | Research and Publications

Increased Comorbidities Linked to Children with Epilepsy

The frequency of comorbid diseases is high in children with epilepsy, even in presumably uncomplicated cases, according to new findings (Pediatrics, September 2016). Using registry data over a five-ye…

Read the full story

Thursday, September 01, 2016 | Acquisitions and Mergers

Sunovion to Acquire Developer of Investigational Parkinson’s Agent

Sunovion Pharmaceuticals has entered a deal to buy Cynapsus Therapeutics, potentially expanding its neurology portfolio to include Parkinson’s disease (PD). Cynapsus’ investigational PD ag…

Read the full story

Thursday, August 25, 2016 | Research and Publications

MR-Guided Focused Ultrasound Shows Promise in Treatment of Essential Tremor

New findings published in The New England Journal of Medicine suggest that MR-guided Focused Ultrasound therapy may represent a viable non-invasive treatment option for the treatment of essential trem…

Read the full story

Thursday, August 25, 2016 | Research and Publications

Expert Panel Calls for Increase in Comparative Effectiveness Research for Alzheimer’s Disease

With effective prevention and treatment of Alzheimer’s disease (AD) still elusive, an expert panel recently called for a boost in comparative effectiveness research as part of a larger effort to…

Read the full story
Load More